Projects will receive funding based upon the following milestones:

  • Upon successful execution of the contract and receipt of appropriate research approvals
  • Upon the Steering Committee's receipt and acceptance of appropriate report at agreed 6-month intervals
  • Upon completion of the research and the Steering Committee's receipt and acceptance of a final report or draft publication

The CF RIA Program Manager must receive copies of appropriate permissions before any award funds will be disbursed.


Funding provided through the CF RIA program may be subject to reporting to the Centers for Medicare and Medicaid Services (CMS) as part of the Sunshine Act. In compliance with the Sunshine Act, Vertex will report annually on payment and other transfers of value made to covered recipients.

A final financial report is due 60 days after the end of the funding period reconciling the proposed budget with the actual expenditures. In the event that unexpended funds remain at the end of the funding period, these funds must be returned to the CF RIA program.


If the award recipient fails to comply with the terms of the agreement or the regulations under the terms of the agreement, Vertex will reserve the right to discontinue award funding.





Written progress reports will be expected by the Steering Committee 6 months from the start of the project and then at agreed 6-month intervals. In addition, the mentor will also be required to provide a brief written progress report at agreed 6-month intervals.


The CF RIA program strongly encourages the award recipients to publish work carried out under an award. This includes abstract submissions to congresses and manuscripts submitted to peer-reviewed journals. Where a publication is not accepted, proof of application is sufficient demonstration. An effort for publication submission must be shown.

The CF RIA program expects all investigators to review the guiding principles set forth by the International Committee of Medical Journal Editors and comply with their registration and publication requirements, which can be found here:


Award recipients will be invited to present their research plan or resulting data at an awards ceremony. Mentors are strongly encouraged to attend the ceremony.

PrivacyTerms of Use
© 2016 Vertex Pharmaceuticals Incorporated | VXR-HQ-00-00016 | 10/2016
CF RIA program funding is supported by Vertex Pharmaceuticals Incorporated

Vertex and the Vertex triangle logo are trademarks of Vertex Pharmaceuticals Incorporated